+86 188 6629 8185
+86 188 6629 8185
603739.SH
Qingdao Vland Biotech Inc. was selected as Top 100 Innovative Private Enterprises in Shandong (Ranked No.7) on July 26, 2024. And it ranked first among the shortlisted Qingdao-based enterprises.
Throughout the years, Vland has been committed to technological innovation with an increase in R&D investment. In 2023, the company's R&D investment accounted for 9.23% of its operating income, a relatively high level in the industry. From 2014 to 2023, the company's cumulative R&D investment accounted for 9.44% of its operating income.
Until now, Vland has established 8 technology centers and 2 labs. With the 8 nation-level innovation platforms and the IPD-based management platform, applicable research has been made in various sectors.
As of 2023, the company and its subsidiaries have been granted 390 authorized Chinese invention patents, 9 authorized U.S patents, 2 authorized European patents, 27 PCT international applications, and 39 new veterinary drug certificates (including 3 Class I new veterinary drugs).
Previous post:
Sports and Love Together - Happy Vland 2025 New Year MarathonNext chapter:
Vland holds“Dancing with Change”Forum 2024Products Category
Related Products
Phytase is a new type of heat stable phytase developed by Vland R&D Center with gene engineering technology. It is suitable for feed pelleting with a pelleting temperature up to 90℃.
KDN lipase is an efficient lipase product developed by Vland Biotech for piglets, poultry and aquaculture to improve their digestion and absorption of lipids in feed.
KDN Xylanase is a non-starch polysaccharides (NSP) enzyme, which can decompose xylans, reduce chyme viscosity and improve the utilization and absorption of nutrients.
KDN Glucanase is a β-Glucanase product containing endo-1,3 (4)-glucanase. Produced by submerged fermentation and particular downstream processing technologies, KDN Glucanase is specifically used to degrade anti-nutritional factor (ANF) of glucans in feed ingredients of plant origin.
